iFAST Diagnostics Bags £5M to Speed UK Antibiotic Resistance Testing

A British biotech that promises to cut antibiotic-choice time from more than 40 hours to under three has closed a £5 million round at almost five times the valuation it carried 18 months ago. Investors agreed to the markup at a moment when the World Health Organization counts antimicrobial resistance among its top 10 global health threats and the Lancet’s GRAM project forecasts 39 million directly attributable deaths between 2025 and 2050.

That headline number, the £5 million, is the easy part of the iFAST Diagnostics story. The harder read sits below it: a £2.1 million non-dilutive loan from Innovate UK inside the same round, a lead investor whose limited partners include three NHS trusts, and a UKCA-certified device already sitting in three British hospital labs at £30 per sample. Together those facts argue that rapid antimicrobial susceptibility testing has crossed the line from research curiosity into procurement-ready category, and the price of being early just reset.

The Deal in Numbers

The round was led by Meridian Health Ventures, the London firm that markets itself as the first NHS-anchored transatlantic healthtech fund. QantX, RAW Ventures and OKG Capital all rolled in from the prior round, along with members of Cambridge Capital Group. The £2.1 million Innovate UK piece is structured as a loan, not equity, which means the £2.9 million of new equity bought a smaller piece of the company than the gross number suggests.

Total invested in the business since its founding three years ago now stands at £12 million. The over-subscription is the line every press release uses; the relevant fact is the valuation step.

Five-times in 18 months is not a venture-norm step for an unprofitable diagnostics business with a single approved indication. It is the price of a thesis that says NHS procurement is finally moving on rapid AST, and that the first device through UKCA with credible clinical data is a defensible position.

Why a 40-Hour Wait Is a Killing Wait

The clinical problem iFAST is pricing into is older than the company. When a blood culture flags positive for sepsis, most UK and European labs still rely on broth microdilution, the gold-standard phenotypic test that takes between 48 and 96 hours from positive bottle to actionable susceptibility result. During that wait the clinician treats empirically, usually with a broad-spectrum antibiotic that may not match the bug and may seed further resistance.

Published reviews of rapid AST in clinical practice put the consequence in concrete terms:

• 38.8 hours of time saved on average to a phenotypic susceptibility result when rapid AST replaces the standard workflow, according to a 2021 review in Frontiers in Medicine.
• 78% of patients in the same review had their therapy optimised once the rapid result landed, against far lower rates in the conventional pathway.
• 51% of those optimisations involved de-escalating to a narrower antibiotic, the single most direct lever clinical labs have on resistance pressure.

Sepsis kills roughly 48,000 people a year in the United Kingdom, by NHS England’s own estimate, and resistance steadily widens the gap between empirical and effective therapy. The £30 cost per test that iFAST quotes is, in that context, a rounding error against an ICU day.

What the iFAST Device Does Differently

The platform is a University of Southampton spin-out built around impedance microfluidics. Bacteria from a positive blood bottle or a raw urine sample are flowed through a chip that measures their electrical properties one cell at a time as they sit in dilutions of different antibiotics. A bug that keeps dividing in the presence of a drug behaves electrically differently from one the drug has killed, and the readout is a resistance call plus a minimum inhibitory concentration in the same window.

From Blood Bottle to Result in Under Three Hours

The published turnaround for the blood-culture indication is under three hours from a positive bottle. For raw urine, the company quotes three to four hours, which removes the overnight culture step entirely. Both numbers describe the device-to-call window, not the time from patient sample to lab.

Cost, Throughput and Drug Coverage

iFAST publishes a £30 per-sample price and a throughput of up to 10 tests per reader per working day, with susceptibility output across up to 15 drugs. Those are operating parameters a NHS microbiology lead can model directly against current workflow costs, which is part of why the device is being placed at all.

Where the Regulatory Story Sits

The UKCA mark covers Gram-negative bacteria from blood cultures, which is the highest-mortality bucket in bloodstream infection. The device is ISO 13485 certified for design and manufacture. EU CE-IVDR submission and a US Food and Drug Administration (FDA, the US medical-device regulator) clearance pathway are both inside the use-of-proceeds for this round, and both are multi-quarter exercises rather than next-quarter events.

Meridian’s NHS-Anchored Bet

The lead investor matters here. Meridian Health Ventures closed a €44.7 million transatlantic fund in 2025 anchored by Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital, University College London Hospitals and the Los Angeles-based Cedars-Sinai Medical Center. Its portfolio already includes a roster of NHS-deployed healthtech companies such as Doccla, Patchwork, Apian and Tympa Health.

Tim Irish, General Partner at Meridian, framed the iFAST bet around clinical practice rather than market size:

The iFAST rapid AST system is a game-changing innovation, delivering susceptibility testing in less than 3 hours, significantly faster than the current standard process which takes more than 40 hours. AMR is one of the defining public health challenges of our generation, and iFAST is taking that challenge head-on with a cost-effective solution already being placed in UK hospital laboratories.

Read against the fund structure, that is investor signalling with teeth. NHS trust LPs are not in the business of buying portfolio narrative; their interest is in devices their own pathology services can buy. A lead position from this fund is a closer thing to a procurement letter of intent than the typical Series A markup.

The Bigger Read on UK Rapid Diagnostics Funding

The iFAST round does not sit on its own. Adjacent rapid-detection plays have closed comparable cheques in the last six months, and the public pot is moving in the same direction.

The UK government’s 2024 to 2029 antimicrobial resistance national action plan made development and use of diagnostics one of its named outcomes, and the National Institute for Health and Care Research has so far put more than £16 million into AMR diagnostics research alone. Government spending across all AMR programmes ran to £567 million between 2020-21 and 2023-24, per the official one-year progress report on the UK 2024 to 2029 AMR national action plan progress report.

On the private side, sibling rounds have followed a similar grammar. German pathogen-detection startup NanoStruct closed a €2.6 million round to cut food-bacteria detection to hours, and London-based NEX Health Intelligence raised £1 million to map hospital superbug spread. Different niches, same investor logic: an AMR data point that lands in hours instead of days is now considered a financeable category, not a science project.

Market analysts have followed the cheques. The global antimicrobial susceptibility testing market sat at roughly $3.5 billion in 2026 by one of the lower-bound estimates and at $4.27 billion in 2025 by another. Automated AST is the fastest-growing slice inside that envelope, with one syndicated forecast pegging it at a 5.82% CAGR through 2033 from a starting point of 38% market share. iFAST’s positioning, automated, phenotypic, sub-three-hour, places it squarely in the segment with the steepest demand curve.

What the Capital Buys Next

Dr Toby King, the company’s chief executive, said the cash will let iFAST stay on its current go-to-market schedule three years after founding rather than slow it. Practically that means three workstreams running in parallel.

First, deeper UK rollout from the existing three-site footprint at Portsmouth, Southampton and Bristol, with SYNLAB and the UK Health Security Agency as the visible commercial partners. Second, CE-IVDR work to open the EU market, where the regulatory file is heavier than UKCA and where reimbursement varies by national payer. Third, the FDA programme, which for a phenotypic AST device typically means a de novo or 510(k) pathway with bridging clinical data from a US site.

The risks are not exotic. EU IVDR delays have stretched timelines across the diagnostics sector since the regime came into force, US clearance for a UK-built phenotypic AST is uncharted at this combination of speed and price, and broth microdilution remains entrenched as the lab-side default. None of those alone breaks the thesis. Together they argue that iFAST’s next 18 months are about converting an oversubscribed financing into hospital purchase orders.

If the EU clearance lands inside 2027 and the US filing opens on schedule, the five-times step looks early rather than rich. If either slips and a competitor with comparable turnaround clears the FDA first, the same step will read as the high-water mark, and the next round will be priced against the gap.